Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lymphoma: experimental drug enters human testing

NCT ID NCT06392477

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an experimental drug called SAR448501 in about 96 adults with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goal is to find the safest and most effective dose by monitoring side effects and how the drug works in the body. Participants will receive the drug for up to a year and be followed for about three years total.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigational Site Number : 001-201

    RECRUITING

    Perth, Western Australia, 6009, Australia

  • Investigational Site Number : 001-202

    RECRUITING

    Townsville, Queensland, 4814, Australia

  • Investigational Site Number : 001-203

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Investigational Site Number : 001-204

    RECRUITING

    Melbourne, Victoria, 3121, Australia

  • Investigational Site Number : 001-205

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Investigational Site Number : 001-401

    RECRUITING

    Busan, 48108, South Korea

  • Investigational Site Number : 001-402

    RECRUITING

    Seoul, 03080, South Korea

  • Investigational Site Number : 001-403

    RECRUITING

    Busan, 49201, South Korea

  • Investigational Site Number : 001-404

    RECRUITING

    Goyang-si, 10408, South Korea

  • Investigational Site Number : 001-405

    RECRUITING

    Seoul, 06351, South Korea

  • Investigational Site Number : 001-501

    RECRUITING

    Taipei, 10048, Taiwan

  • Investigational Site Number : 001-502

    RECRUITING

    Kaohsiung City, 83301, Taiwan

  • Investigational Site Number : 001-503

    RECRUITING

    Changhua, 505, Taiwan

  • Investigational Site Number : 001-601

    RECRUITING

    Singapore, 119074, Singapore

  • Investigational Site Number : 001-602

    RECRUITING

    Singapore, 308433, Singapore

  • Investigational Site Number : 001-703

    ACTIVE_NOT_RECRUITING

    Kamenitz, 21204, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.